Greenberg Traurig, LLP has more than 3,100 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm’s broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI “Best of the Best Recommended Law Firm” by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.
Patents serve as the fundamental currency of the medical technology industry, enabling companies to raise capital, form strategic alliances, and generate licensing revenue. Yet many medtech innovators fail to treat their intellectual property as a core business asset, risking the loss of competitive advantage and market exclusivity that could diminish the full value of their innovations.
David J. Dykeman’s articles from Greenberg Traurig, LLP are most popular:
within Intellectual Property topic(s)
in India
Patents are the currency of the medical technology industry and fundamental to the success of any medtech company. A medtech company can leverage its intellectual property (IP) in many ways including: raising capital, entering into strategic alliances, using licensing to generate revenue, blocking competitors, and through joint ventures, mergers, acquisitions and initial public offerings (IPOs).
However, medtech innovators need to approach IP as a core business asset, or risk losing competitive advantage, market exclusivity, and ultimately the full value of their innovations.
The content of this article is intended to provide a general guide
to the subject matter. Specialist advice should be sought about your
specific circumstances.
